Patents Assigned to GeneDesign, Inc.
  • Patent number: 11479769
    Abstract: Provided is a novel technique for treating cancer using structurally-reinforced S-TuD. Provided are: a composition for the prevention or treatment of tumors, said composition comprising an miRNA inhibitory complex including RNA of analog thereof; and a method for preventing or treating tumors using said composition. The miRNA inhibitory complex preferably includes at least one double-stranded structure and an miRNA-binding sequence. Two strands of the miRNA binding sequence preferably bind individually to two strands on at least one end of the double-stranded structure. According to some of the aspects of the present invention, there is provided a delivery system for delivering such an miRNA inhibitory complex.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 25, 2022
    Assignees: National University Corporation Chiba University, GeneDesign, Inc., NOF Corporation
    Inventors: Hideo Iba, Takeshi Haraguchi, Hirokazu Nankai, Hideaki Sato
  • Patent number: 11453880
    Abstract: Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 27, 2022
    Assignees: ANGES, INC., GENEDESIGN, INC.
    Inventors: Ryuichi Morishita, Takashi Miyake, Tetsuo Miyake, Takahiro Nakazawa, Makoto Sakaguchi, Satoshi Inoue, Ryoji Ueki
  • Patent number: 11268098
    Abstract: Provided are non-aggregating immunostimulatory oligonucleotides. The present invention also provides a delivery agent for an immunostimulatory-oligonucleotide nucleic acid medicine, said delivery agent including a nucleic acid that contains a phosphorothioated nucleotide. According to another aspect, the present invention further provides an oligonucleotide including a bioactive core, and a nucleic acid that contains a phosphorothioated nucleotide. The present invention yet further provides an immunostimulator including the bioactive core of a type A/D, type B/K, or type C immunostimulatory oligonucleotide.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: March 8, 2022
    Assignees: National Institutes of Biomedical Innovation, Health and Nutrition, GeneDesign, Inc.
    Inventors: Ken Ishii, Taiki Aoshi, Hideaki Sato
  • Patent number: 11174279
    Abstract: The present invention pertains to a method for synthesizing a ribonucleic acid H-phosphonate monomer, and a method for performing oligonucleotide synthesis in which said monomer is used. The present invention pertains to a method for manufacturing an inexpensively manufacturable H-phosphonate nucleoside derivative in which selective protection is provided to position 2? of a ribonucleoside monomer required in RNA oligonucleotide synthesis. The present invention is characterized in that: hydroxyl groups in position 2? and position 3?, which have slightly different reactivity, are caused to react with an aromatic acyl halide at low temperature to selectively esterify position 2?; and subsequently the hydroxyl group at position 3? in one pot is captured by a phosphityl group to prevent position 2? and position 3? transfer of the acyl group.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 16, 2021
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, GeneDesign, Inc.
    Inventors: Satoshi Inoue, Kohei Himeno, Hirokazu Nankai, Mutsuo Tanaka, Teiichi Murakami
  • Patent number: 10844376
    Abstract: The present invention pertains to the improvement of a miRNA inhibitor (a synthesized Tough Decoy (S-TuD)). The present invention provides a miRNA inhibitory complex including RNA or an analog thereof, wherein the RNA inhibitory complex includes at least one double-stranded structure and a miRNA binding sequence, each of two strands of the miRNA binding sequence being bound to two strands of at least one end of the double-stranded structure, and the miRNA inhibitory complex further includes at least one crosslinked nucleic acid.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 24, 2020
    Assignees: University of Tokyo, GeneDesign, Inc.
    Inventors: Hideo Iba, Takeshi Haraguchi, Hirokazu Nankai, Hideaki Sato
  • Publication number: 20180298381
    Abstract: Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.
    Type: Application
    Filed: September 9, 2016
    Publication date: October 18, 2018
    Applicants: AnGes, Inc., GeneDesign, Inc.
    Inventors: Ryuichi MORISHITA, Takashi MIYAKE, Tetsuo MIYAKE, Takahiro NAKAZAWA, Makoto SAKAGUCHI, Satoshi INOUE, Ryoji UEKI